Ascentage Pharma Group International reported unaudited financial results for the six months ended June 30, 2026. Revenue increased 29% year-over-year to US$44.5 million (RMB302.2 million), driven by a 32.6% rise in product sales to US$41.6 million. The company posted a net loss of US$120.4 million, compared to US$82.5 million in the prior year period. Cash and bank balances decreased 23.3% to US$279.4 million due to increased research and development expenses associated with global clinical trials. Ascentage Pharma appointed Dr. Faiçal Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer. The company also removed the “B” marker from its Hong Kong Stock Exchange short name, indicating it met higher market capitalization and revenue thresholds. Ascentage Pharma is a global biopharmaceutical company engaged in the discovery, development, and commercialization of novel cancer therapies.
